Decitabine (DAC)
Sponsors
M.D. Anderson Cancer Center, National Cancer Institute (NCI), Nanfang Hospital, Southern Medical University, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Conditions
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATIONAllogeneic Hematopoietic Stem Cell TransplantationCarcinoma, EsophagealCarcinoma, Non-Small-Cell LungConditioningHematopoietic Stem Cell Transplantation (HSCT)LeukemiaLung Cancer
Phase 1
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia
CompletedNCT00002831
Start: 1995-08-01End: 2002-12-31Updated: 2018-10-26
Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy
WithdrawnNCT02839694
Start: 2016-07-07End: 2017-04-26Updated: 2018-07-05
Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas
TerminatedNCT03233724
Start: 2018-04-11End: 2021-10-26Updated: 2023-05-31
Phase 2
Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)
CompletedNCT02269280
Start: 2014-10-13End: 2024-07-25Updated: 2025-08-07
G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for RAEB-1,REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT
NCT04713956
Start: 2021-01-15End: 2024-07-31Target: 242Updated: 2021-01-19
G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for Secondary Acute Myeloid Leukemia Undergoing Allo-HSCT
NCT05449899
Start: 2022-07-31End: 2024-12-31Target: 232Updated: 2022-07-08
G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCT
NCT05453552
Start: 2022-07-01End: 2024-12-31Target: 242Updated: 2023-03-21
Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention
RecruitingNCT06686108
Start: 2024-10-30End: 2028-10-30Target: 59Updated: 2025-05-07
VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT
Not yet recruitingNCT07052422
Start: 2025-07-15End: 2029-12-31Target: 160Updated: 2025-07-04